Pedersen Lars Møller

July 2023: h-index: 30 (Web of Science) Citations: 5385 i10-indeks: 53 Number of peer reviewed publications: 73 More than 60 peer reviewed abstracts and oral presentations at international conferences. PhD supervisor 4 completed courses and 5 ongoing courses (University of Southern Denmark and University of Copenhagen). Supervisor 5 master and bachelor theses. Chairman at several national and international symposia and meetings. National coordinating and principal investigator in several national and international clinical trials. Sponsor role in multicenter studies. Extensive GCP experience and certified GCP education. Writing and implementation of several protocols covering clinical trials and basic research projects. National and international lectures. Clinical associate research professor at the University of Copenhagen and Southern Denmark. Co-founder of the Danish Lymphoma Group (2000). Board member of the Danish Society of Hematology (DHS), Danish Lymphoma Group (DLG) and Nordic Lymphoma Group (NLG). Head of the Lymphoma Division at Herlev University Hospital and Odense University Hospital. Head of Clinical Research Unit, Roskilde Hospital and Herlev University Hospital. Member of Independent Review Committees (IRC) evaluating international clinical studies. Member of the steering group in several clinical trials. Invited peer reviewer in six international medical journals. Chairman of the lymphoma committee in the Danish Medicines Council (Medicinrådet 2017-2023). Member of the Danish Health Authority's expert panel for cancer ("second opinion" 2018-2023). Scientific focus areas: Metabolic response evaluation and lymphoma: initiator to and principal investigator in the first international PET study in Hodgkin lymphoma and a later international trial in diffuse large B-cell lymphoma in collaboration between Nordic Lymphoma Group and Mount Sinai Hospital, New York. Immunotherapy and lymphoma: as a member of the steering committee, initiator of international studies which changed treatment practices for lymphomas. Consultant for the Danish company Genmab in the development of a second generation human CD20 antibody. National coordinator in subsequent phase 1-2 trials. Member of independent review committees in Genmabs and Glaxo Smith Klines phase 1-2 studies of treatment with human 2nd generation anti-CD20 for CLL. Vaccination strategies with PD-L1 and PD-L2 peptides and lymphoma: collaboration with Center for Cancer Immune Therapies (CCIT) in first in human studies. Inflammation and lymphoma: studies of cytokine expressions and other biomarkers at the hematological laboratory at Herlev University Hospital. Molecular biomarkers and lymphoma: studies of molecular biology in diffuse large B-cell lymphoma in cooperation with the Nordic Lymphoma Group, the Institute of Pathology, Odense University Hospital, and international groups. Quality of life and lymphoma: studies using PRO as a tool in the clinical management of lymphoma patients. QoL and sexual dysfunction as late toxicity after cancer treatment. The studies are carried out in collaboration with the Danish Cancer Society and CASTLE. Clinical trials and lymphoma: sponsor, national and principal investigator in several clinical trial phase 1-3 both sponsored by the pharmaceutical industry and investigator-initiated protocols.